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ABSTRACT
We study the problem of detecting adverse drug events in electronic
healthcare records. e challenge in this work is to aggregate het-
erogeneous data types involving diagnosis codes, drug codes, as
well as lab measurements. An earlier framework proposed for the
same problem demonstrated promising predictive performance for
the random forest classier by using only lab measurements as data
features. We extend this framework, by additionally including diag-
nosis and drug prescription codes, concurrently. In addition, we em-
ploy a recursive feature selection mechanism on top, that extracts
the top-k most important features. Our experimental evaluation
on ve medical datasets of adverse drug events and six dierent
classiers, suggests that the integration of these additional features
provides substantial and statistically signicant improvements in
terms of AUC, while employing medically relevant features.
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1 INTRODUCTION
Adverse drug events (ADEs) refer to injuries caused by medication
errors, allergic reactions or overdoses, and are related to drugs
[1]. Before a medicine is released to the market, in clinical trials, a
rigorous approach is followed to test their ecacy and safety in a
rather limited cohort of patients [8]. Aer the authorization and
while the medicine is used from a large number of patients for an
extended period of time, it can result to unwanted ADEs. More
than half of the ADEs that lead to Emergency Department visits
are preventable, but half of those are not reported since they are
not easily identiable [7]; hence resulting in unnecessary human
suering and a burden in the healthcare sector. An alternative
approach is to employ machine learning methods in post-market
surveillance, by exploiting the abundant information available in
Electronic Health Records (EHRs) to identify ADEs that did not
appear during the stage of clinical trials.
More concretely, a patient case in an EHR consists of a number
of medical variables, such as diagnoses (in the form of ICD10 1
codes) and medications (in the form of ATC codes 2), lab measure-
ments, and other clinical procedures that characterize the history
of each patient. ese could potentially act as highly informative
features towards ADE prediction, and as as such, should be care-
fully taken into consideration in the learning process in order to
make medically sound predictions. Nevertheless, EHR data are
inherently sparse and heterogeneous, and as a result may contain a
1hps://www.icd10data.com/ICD10CM/Codes
2hps://www.whocc.no/atc ddd index/
large fraction of empty values (see, e.g., Bagaini et al. [2]), hence
introducing critical challenges that need to be addressed in order
to achieve stronger predictive models.
Previous research in ADE prediction has focused on utilizing
structured data or clinical text (e.g., [9, 10, 12]) from EHRs and on
extracting static features for learning predictive models.
Zhao et al. utilize the structure of clinical codes (medication and
diagnoses codes) and explores dierent ways to represent them
[13, 14], while other related research consider the temporal aspect of
clinical codes and measurements, and employ predictive modeling
to identify previously unseen ADEs [10, 11, 15]. Moreover, the use
of natural language processing has been investigated for obtaining
models that are able to predict unseen ADEs based on unstructured
data, such as clinical text [5, 9]. Recent work by Bagaini et al.
[2] focuses on optimizing the random forest classier for ADE
prediction by taking into account the temporal nature and sparsity
that characterizes clinical lab measurements, and employs them as
the only predictors for ADE classication [2].
To the best of our knowledge existing approaches for ADE predic-
tion using EHRs have been mainly focusing on optimizing specic
predictive models for a particular data source or data type. On
the other hand, very limited aention has been given to building
models that combine multiple heterogeneous data sources, while
addressing feature sparsity and heterogeneity, as well as taking
into consideration the nature of each predictor.
e main goal of this paper is, hence, to incorporate dierent het-
erogeneous EHR features that can improve ADE discovery. Speci-
cally, this paper extends the framework proposed by Bagaini et
al. [2] by (1) including additional features and data types from a
patient record, except for using only lab measurements, and (2) by
benchmarking the proposed approach on six classication models
instead of only the random forest classier. As shown in the experi-
mental evaluation these additional features, i.e., drug and diagnoses
codes, in conjunction with the clinical measurements as well as a
recursive feature importance strategy, can have a detrimental eect
in ADE detection, resulting in signicant improvements in terms
of AUC for several ADE types.
e contributions of this paper include: (a) the presentation
of a workow for ADE prediction using multiple data sources ex-
tracted from EHRs, that consists of two phases: feature aggregation,
and recursive feature selection and predictive modeling; (b) the
investigation of six classication models and eight feature integra-
tion approaches for ADE prediction; (c) an extensive experimental
evaluation on the ve most popular ADEs in the Stockholm EPR
Corpus extracted from HealthBank [3] exploring all combinations
of the three proposed feature types, as well as using six dierent
classication models.
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2 AGGREGATE - ELIMINATE - PREDICT
We rst present the feature aggregation phase of our workow, fol-
lowed by the recursive feature elimination and predictive modeling
phase in more detail.
2.1 Feature Aggregation
Let E = {E1, . . . ,En } denote an EHR of a single patient, where
each Ei represents a medical event, and is represented by a triplet
(e,v, t), with Ei .e ∈ T being the event type over a set of possible
event types T = {t1, . . . , tk }, Ei .v being the event value, and Ei .t
the event timestamp. In this paper, we consider two types of events,
i.e., k = 2: categorical and continuous. Medical diagnoses and drug
prescriptions (i.e., ATC and ICD10 codes) belong to the rst case,
while lab measurements belong to the second case.
Consider a set of EHRs denoted as D = {E1, . . . ,Em } over m
patients, and a time window w = {ts , te } dened at a particular
location of interest in each Ei , ending at time point te (e.g., at the
occurrence of an ADE) and spanning w time points before te . e
task is to extract a set of aggregated features over time for each Ei .
Let Eiw = {Eij , . . . ,Eij′} be the subsequence of events in Ei starting
at timestamp ts and ending at te . Practically, Eij′ corresponds to the
last event in Ei such that Eij′ .t ≤ te and Eij is the “earliest” event
event in the time window w , such that Eij .t ≥ ts .
For each distinct categorical event Ej in Eiw , we count how many
times Ej occurs in w , and assign this value as the feature value
for this event. For the case of a continuous event Ej , we apply
the lr transformation described in Baggatini et al. [2], such that
lr (Ej ) maps the continuous feature to a real value capturing the
underlying temporal structure in Ej . ese transformations result
into a tabular transformation of each Ei ∈ D, denoted as τw (Ei ),
for a given window size w .
is results in a new transformed EHR dataset containing aggre-
gated features, using the above representation. is new aggregated
dataset is denoted as Dˆw = {τw (E1), . . . ,τw (Em )}.
2.2 Recursive Feature Elimination and
predictive modeling
e converted EHR dataset Dˆw is passed to a recursive feature
elimination mechanism that recursively identies the top-k most
informative features.
LetM(0) = f (Dˆw ) denote the model built using the aggregated
dataset Dˆw and a given predictive modeling function f (·). For
example, f (·) can correspond to a decision tree induction algorithm
or to the random forest algorithm. e main steps of this procedure
are as follows: a signicant level α is set, and at each iteration i:
• the feature with the highest gini importance is identied,
and if the value is greater than the signicance level α , the
feature is removed;
• a new model,M(i), built using the remaining feature set.
e process is repeated until the removal of any feature that reduces
the AUC of the model in a validation set below a given threshold β
or k features are selected. is results in the nal model, which we
denote asM(k ).
Figure 1: An EHR sequence and a window of interestw .
3 EXPERIMENTAL EVALUATION
3.1 Data and Setup
e medical database consists of information about diagnoses, med-
ications, blood and laboratory values for 1,314,646 patients obtained
from Health Bank at Stockholm University [3]; an anonymized pa-
tient record from the TakeCare CGM patient record system used
at Karolinska University Hospital in Stockholm, Sweden. Struc-
tured data are labelled using common encoding systems such as the
Anatomical erapeutic Chemical Classication System (ATC) for
medications, the International Statistical Classication of Diseases
and Related Health Problems, 10th Edition (ICD-10) for diagnoses
as well as the Nomenclature, Properties and Units (NPU) coding
system 3 for clinical laboratory measurements.
e performance of the proposed workow has been evaluated
using the following benchmarked classication algorithms: (1)Ran-
dom Forests with 100 trees and gini impurity as the split criterion,
Support Vector Machines(SVM) with weighted class balance and
(2)linear kernel, (3)polynomial kernel, (4) RBF kernel, (5) a Multi-
layer-percepton(MLP) with 3 hidden layers and (6)eXtreme Gradi-
ent Boosting(XGB) with 100 trees. All models were trained in the 8
feature integration approaches. Since the datasets in this study are
imbalanced, the evaluation metric we used is the Area Under the
ROC Curve (AUC), as it has been shown to be an appropriate metric
for imbalanced datasets, not biased towards the majority class [2, 6]
and was obtained from stratied 10-fold cross-validation.
3.2 Results
Table 1 presents our experimental ndings in terms of predictive
modelling. e rst experiment focused on extending the work of
Bagaini et al. [2] incorporating features of other types while only
using Random Forests, for easier comparison with the proposed
framework. It can be seen that for the the integrated set of lab
measurements, medication and diagnoses codes (LDM), Random
Forest consistently outperformed the integration approach with
only the lab values (L). Specically, 4 out of 5 studied ADEs showed
an improvement, in terms of mean AUC over stratied 10-fold cross-
validation, ranging from 4 to 10 %. is indicates that a pool of
dierent medical features can constitute promising ADE predictors,
even though the dimensionality of the feature space increases.
Furthermore, we provide a statistical analysis for the 7 integra-
tion approaches of the 5 ADEs, using the Random Forest classier,
to identify if the investigated approaches perform equally well. We
use the Friedman test followed by Nemenyi post-hoc test when
the null hypothesis is rejected [4]. e Friedman test returned a p
3hp://www.ifcc.org/ifcc-scientic-division/sd-commiees/c-npu/
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Table 1: AUC obtained by 6 classiers on 5 ADE datasets; e AUC reported is averaged over stratied 10-fold cross validation;
in bold: the best AUC for each classier; underlined: highest AUC for each ADE; In 8 integration approaches denoted as L:lab
measurements, M:ATC, D:ICD-10, LM: labs and ATC, LD: labs and ICD-10, MD:ATC and ICD-10, LMD:labs, ATC and ICD-10.
ADE classier L M D LM LD MD LMD LMD k best
D611 RF100 0.8583 0.9226 0.8871 0.8965 0.8867 0.9311 0.9172 0.9166
SVMLin 0.8360 0.8338 0.7782 0.8429 0.8388 0.7804 0.8230 0.9137
SVMPoly 0.8278 0.6314 0.4774 0.6642 0.6229 0.4451 0.4606 0.8897
SVMrbf 0.8675 0.8073 0.7381 0.8568 0.8221 0.8028 0.8547 0.9137
MLP 0.8554 0.8230 0.7566 0.8707 0.8170 0.8140 0.8573 0.9076
XGB 0.8494 0.9149 0.8939 0.9184 0.8961 0.9306 0.9332 0.9243
G620 RF100 0.8376 0.7200 0.8166 0.8677 0.8625 0.8598 0.8890 0.8982
SVMLin 0.7037 0.6379 0.7314 0.7148 0.7476 0.7198 0.7746 0.8299
SVMPoly 0.7198 0.6741 0.2787 0.7196 0.3674 0.3373 0.3898 0.7914
SVMrbf 0.8070 0.7272 0.7619 0.8006 0.7667 0.7683 0.7967 0.9147
MLP 0.6577 0.7276 0.7505 0.7622 0.7667 0.7744 0.7800 0.8211
XGB 0.8351 0.7620 0.8242 0.8510 0.8595 0.8704 0.8770 0.8886
T784 RF100 0.5939 0.7081 0.6032 0.7250 0.6591 0.7307 0.7616 0.7608
SVMLin 0.6443 0.6188 0.5996 0.6287 0.6080 0.6362 0.5974 0.6417
SVMPoly 0.4685 0.4840 0.4608 0.4437 0.4601 0.4407 0.4161 0.5513
SVMrbf 0.6377 0.7033 0.6079 0.7208 0.6167 0.6695 0.6877 0.7365
MLP 0.5871 0.6358 0.5993 0.6237 0.5921 0.6340 0.6374 0.6864
XGB 0.6298 0.7108 0.6146 0.7235 0.6316 0.7374 0.7417 0.7460
T808 RF100 0.8910 0.8888 0.8679 0.9109 0.9293 0.9320 0.9320 0.9364
SVMLin 0.7873 0.7058 0.7768 0.7967 0.8176 0.8315 0.8509 0.8721
SVMPoly 0.8074 0.6930 0.7741 0.7729 0.7949 0.7861 0.8109 0.8927
SVMrbf 0.8903 0.8168 0.8112 0.8918 0.8453 0.8262 0.8547 0.9389
MLP 0.7841 0.7589 0.7867 0.8405 0.8432 0.8454 0.8825 0.9132
XGB 0.8900 0.8875 0.8894 0.9165 0.9078 0.9226 0.9204 0.9206
T887 RF100 0.6533 0.7308 0.7029 0.7832 0.7399 0.7652 0.7873 0.7868
SVMLin 0.6797 0.6417 0.6275 0.6560 0.6540 0.6573 0.6744 0.7269
SVMPoly 0.6835 0.6457 0.4529 0.6169 0.4762 0.4873 0.3876 0.7356
SVMrbf 0.7002 0.7222 0.6682 0.7648 0.7130 0.7262 0.7518 0.7683
MLP 0.6280 0.6612 0.6530 0.7135 0.6930 0.6843 0.7046 0.6989
XGB 0.6813 0.7352 0.6773 0.7762 0.7353 0.7759 0.7932 0.7951
value of 2.922e-05 indicating that among the proposed integration
approaches there is at least one that statistically diers from the
others. Figure 2 depicts the results of the post-hoc Nemenyi test
where it can be observed that the LMD integration approach is
statistically dierent from the datasets that contain the lab mea-
surements(L), the diagnoses codes(D) as well as the fusion of lab
and diagnoses codes(LD).
Next, we investigate the eect of other classiers in all the in-
tegration approaches. Before feature elimination we observe that
in the LMD integration approach, for ADEs D61.1 and T88.7, XGB
yielded slightly beer results, with random forest being the winner
in G62.0, T78.4 and T80.8. e last column of table 1 presents the
mean AUC obtained for the k best features aer feature elimination.
For D61.1 and G62.0 k=55, for T78.4 k=270, for T80.8 k=190 and
lastly for T88.7 k=120, where k is the number of optimal features.
It can be observed that across most classiers and for all studied
ADEs the feature elimination approach notably yielded beer re-
sults. Note that when comparing the last two columns(LMD and
LMD k best) it can be seen that the SVM classiers had a notewor-
thy increase in mean AUC, while Random Forest and XGB in most
cases slightly improved.
Figure 2: post-hoc Nemenyi test for multiple comparison of
the 7 integration approaches using the Random Forest clas-
sier, excluding the one obtained by RFE.
3.3 Medical relevance
Feature importance for the integrated datasets that contain the lab
measurements, medication and diagnoses codes, before and aer
feature elimination, indicated the following among the most impor-
tant features chosen by the Random Forest classier: NPU03568,
NPU01944, A04AA01, Z51.1. According to the literature, irregu-
lar levels of NPU03568 (rombocytes/platelets) and NPU01944
3
(Erythrocytes) 4 are indicators of aplastic anaemia 5, Z51.1 (En-
counter for antineoplastic chemotherapy) is a cancer treatment re-
lated to/can cause aplastic anaemia 6 and lastly drug code A04AA01
(ondansetron, in the category of antiemetics and antinauseants) was
found to be a drug administered to patients that undergo chemother-
apy to prevent nausea and vomiting 7.
Figure 3: Feature importance on D61.1 aer feature elimina-
tion
4 CONCLUSIONS
We presented a workow for predicting ADEs from EHRs using
multiple disparate and complex medical data sources. We demon-
strated the importance of incorporating dierent heterogeneous
EHR features in the learning process, compared to only using lab
measurements as it can improve ADE discovery and lead to medical
sound predictions. Furthermore, we illustrated the importance of
feature elimination and employing medically relevant features as it
can substantially improve the classication task. Future research
should focus on incorporating other types of features such as clini-
cal text, investigate the temporal aspect of all features used, as well
as study the eect of dynamically choosing dierent patient history
lengths per feature.
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